Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▼ −3.7% | ▼ −0.5% | ▲ +10.9% | ▲ +20.0% | ▲ +25.7% | ▲ +68.1% | ▼ −16.7% | ▲ +83.3% |
| Peer average | ▼ −1.0% | ▲ +4.4% | ▲ +6.3% | ▲ +20.3% | ▲ +29.0% | ▲ +76.0% | ▲ +28.4% | — |
| S&P 500 · VOO | ▼ −0.5% | ▼ −2.3% | ▼ −2.2% | ▲ +11.2% | ▲ +11.8% | ▲ +89.5% | ▲ +77.1% | — |
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2025-12-30 | 2026-01-08 | $0.14 |
| 2021-12-30 | 2022-01-07 | $0.00 |
| 2021-12-13 | 2021-12-21 | $0.11 |
| 2020-12-14 | 2020-12-23 | $0.05 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind HELX.